Cite
HARVARD Citation
Tolcher, A. et al. (n.d.). 338 Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma. European journal of cancer. pp. S66-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Tolcher, A. et al. (n.d.). 338 Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma. European journal of cancer. pp. S66-. [Online].